Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy’s Revises Wockhardt Terms In Light Of COVID-19 Slump

Deal Restructured After Wockhardt Unit’s Sales Fall In March And April

Executive Summary

Dr Reddy’s has completed its deal for Wockhardt’s branded generics business. However, the two companies have renegotiated the financial terms of the deal following the impact of the COVID-19 pandemic on Wockhardt’s business.

You may also be interested in...



New Faces Feature In Industry Top 50

In the third and final part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies, one or two new entrants appeared towards the bottom of the top 50.

Dr Reddy’s International Business Makes Up For Domestic Decline

Dr Reddy’s saw growth particularly in Europe, North America and international markets in the firm’s financial first quarter ended June 2020. However, the company’s domestic business saw a decline of a due to the impact of COVID-19.

Wockhardt Eyes US Biosimilars In Wake Of Reddy’s Deal

India’s Wockhardt says that developing biosimilars for the US will be one of its strategic priorities after the divestment of parts of its branded generics business to Dr Reddy’s unlocks “adequate liquidity for robust growth in international operations.” The firm remains upbeat about its future prospects despite its annual results revealing a widespread sales slump, albeit coupled with a recovery in profitability.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel